MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Penumbra Accounts Receivables 2011-2026 | PEN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Penumbra
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 190 M | 168 M | 202 M | 203 M | 134 M | 115 M | 106 M | 81.9 M | 58 M | 43.3 M | 29.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 203 M | 29.4 M | 121 M |
Quarterly Accounts Receivables Penumbra
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 183 M | 176 M | 168 M | 176 M | 201 M | 192 M | 207 M | 209 M | 207 M | 203 M | 189 M | - | 143 M | 134 M | 120 M | - | 126 M | 115 M | 115 M | 115 M | 115 M | 106 M | 106 M | 106 M | 106 M | 81.9 M | 80.4 M | 74.1 M | 65.1 M | 58 M | 58 M | 58 M | 58 M | 43.3 M | 43.3 M | 43.3 M | 43.3 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 18.9 M | 18.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 209 M | 18.9 M | 107 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
26.2 M | $ 34.74 | 0.8 % | $ 1.6 B |  USA |
 |
Align Technology
ALGN
|
996 M | $ 186.13 | 0.78 % | $ 13.9 B | USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 12.68 | -0.74 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Inogen
INGN
|
38.9 M | $ 6.3 | -0.71 % | $ 168 M | USA |
 |
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.02 | -0.49 % | $ 17.3 M | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bio-Rad Laboratories
BIO
|
452 M | $ 296.27 | 1.31 % | $ 8.36 B | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.41 | 3.28 % | $ 128 M |  France |
 |
Bruker Corporation
BRKR
|
566 M | $ 39.67 | -0.59 % | $ 5.91 K | USA |
 |
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.6 | 1.14 % | $ 37.3 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
LENSAR
LNSR
|
6.38 M | $ 6.19 | 2.48 % | $ 74 M | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 1.97 | -0.76 % | $ 1.2 M | USA |
 |
ClearPoint Neuro
CLPT
|
6.55 M | $ 10.47 | 0.82 % | $ 296 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Myomo
MYO
|
4.1 M | $ 0.8 | 0.52 % | $ 33.5 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
24.7 M | $ 25.61 | 1.59 % | $ 217 M | USA |
 |
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
178 K | $ 2.8 | - | $ 7.77 M | USA |
 |
Globus Medical
GMED
|
679 M | $ 94.71 | -0.24 % | $ 12.8 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 18.07 | 1.18 % | $ 424 M | USA |
 |
Butterfly Network
BFLY
|
20.8 M | $ 4.79 | 7.77 % | $ 1.01 B | USA |
 |
Tactile Systems Technology
TCMD
|
43.9 M | $ 25.33 | 1.08 % | $ 579 M | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
11.7 M | $ 10.9 | 0.18 % | $ 390 M | USA |
 |
Tandem Diabetes Care
TNDM
|
165 M | $ 21.13 | 0.09 % | $ 1.44 B | USA |
 |
Inspire Medical Systems
INSP
|
120 M | $ 57.54 | 1.25 % | $ 1.69 B | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 39.18 | -1.38 % | $ 1.22 B | USA |
 |
LivaNova PLC
LIVN
|
216 M | $ 65.53 | 0.82 % | $ 3.57 B |  Britain |